BIOMAT Database Logo BIOMAT Database Logo

[Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia]. 1994

E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Hématologie Clinique, CHU Le Bocage, Dijon, France.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D011803 Quinine An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. Biquinate,Legatrim,Myoquin,Quinamm,Quinbisan,Quinbisul,Quindan,Quinimax,Quinine Bisulfate,Quinine Hydrochloride,Quinine Lafran,Quinine Sulfate,Quinine Sulphate,Quinine-Odan,Quinoctal,Quinson,Quinsul,Strema,Surquina,Bisulfate, Quinine,Hydrochloride, Quinine,Sulfate, Quinine,Sulphate, Quinine
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
January 1994, Medical and pediatric oncology,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
January 1988, Medical and pediatric oncology,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
January 1985, Investigational new drugs,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
September 1984, Seminars in oncology,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
June 1985, Onkologie,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone in relapsed and refractory acute leukemia.
September 1984, Seminars in oncology,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.
January 1989, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone for refractory and relapsed acute leukemia.
August 1990, Cancer,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
January 1990, Nouvelle revue francaise d'hematologie,
E Solary, and F Witz, and P Moreau, and I Quiquandon, and P Genne, and M Flesch, and A Saddoun, and F Maloisel, and B Pignon, and J F Abgrall
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
August 1991, Cancer,
Copied contents to your clipboard!